Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMM9ORD)

Drug Name
ASG-15ME Drug Info
Indication
Disease Entry ICD 11 Status REF
Bladder cancer 2C94 Phase 1 [1]
Urothelial carcinoma 2C92.0 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMM9ORD

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
SLIT and NTRK-like family member 6 (SLITRK6) TTTVEKI SLIK6_HUMAN Not Available [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Bladder tissue
The Studied Disease Bladder cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
SLIT and NTRK-like family member 6 (SLITRK6) DTT SLITRK6 7.13E-05 -2.93 -3.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01963052) ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Seattle Genetics.